Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07069712

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Led by AstraZeneca · Updated on 2026-04-23

100

Participants Needed

70

Research Sites

163 weeks

Total Duration

On this page

Sponsors

A

AstraZeneca

Lead Sponsor

P

Parexel

Collaborating Sponsor

AI-Summary

What this Trial Is About

GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.

CONDITIONS

Official Title

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed gastric, gastroesophageal junction, or esophageal adenocarcinoma that can be surgically removed
  • Participants must be CLDN18.2-positive and HER2-negative for Sub-study 1, HER2-positive for Sub-study 2, or have no specific biomarker requirements for Sub-study 3
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ and bone marrow function
  • Body weight greater than 35 kg
Not Eligible

You will not qualify if you...

  • Prior anti-cancer treatment or surgery for the current gastric, gastroesophageal junction, or esophageal cancer
  • Active or past autoimmune or inflammatory disorders needing systemic steroids or immunosuppressive treatment
  • Central nervous system pathology
  • Uncontrolled infections
  • History or presence of interstitial lung disease or pneumonitis
  • History of another primary cancer
  • Known or suspected distant metastasis
  • Uncontrolled or active hepatitis B infection
  • Use of immunosuppressive medication within 14 days before the first study treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 70 locations

1

Research Site

Newark, Delaware, United States, 19713

Actively Recruiting

2

Research Site

Washington D.C., District of Columbia, United States, 20007

Actively Recruiting

3

Research Site

Fairway, Kansas, United States, 66205

Actively Recruiting

4

Research Site

North Shores, Michigan, United States, 49444

Actively Recruiting

5

Research Site

New York, New York, United States, 10032

Not Yet Recruiting

6

Research Site

New York, New York, United States, 10065

Actively Recruiting

7

Research Site

Pittsburgh, Pennsylvania, United States, 15232

Not Yet Recruiting

8

Research Site

Toronto, Ontario, Canada, M5G 2M9

Suspended

9

Research Site

Montreal, Quebec, Canada, H2X 3E4

Actively Recruiting

10

Research Site

Montreal, Quebec, Canada, H4A 3J1

Actively Recruiting

11

Research Site

Beijing, China, 100142

Actively Recruiting

12

Research Site

Changchun, China, 130021

Actively Recruiting

13

Research Site

Changzhi, China, 046000

Actively Recruiting

14

Research Site

Chengdu, China, 610041

Actively Recruiting

15

Research Site

Chengdu, China, 610042

Actively Recruiting

16

Research Site

Fuzhou, China, 350014

Not Yet Recruiting

17

Research Site

Hangzhou, China, 310003

Actively Recruiting

18

Research Site

Hangzhou, China, 310014

Actively Recruiting

19

Research Site

Kunming, China, 650118

Actively Recruiting

20

Research Site

Qingdao, China, 266003

Actively Recruiting

21

Research Site

Shanghai, China, 200025

Actively Recruiting

22

Research Site

Shijiazhuang, China, 050020

Withdrawn

23

Research Site

Tbilisi, Georgia, 0112

Actively Recruiting

24

Research Site

Tbilisi, Georgia, 0114

Actively Recruiting

25

Research Site

Tbilisi, Georgia, 0144

Actively Recruiting

26

Research Site

Tbilisi, Georgia, 0159

Actively Recruiting

27

Research Site

Florence, Italy, 50134

Actively Recruiting

28

Research Site

Milan, Italy, 20133

Actively Recruiting

29

Research Site

Milan, Italy, 20141

Actively Recruiting

30

Research Site

Milan, Italy, 20162

Actively Recruiting

31

Research Site

Modena, Italy, 41124

Withdrawn

32

Research Site

Pisa, Italy, 56100

Actively Recruiting

33

Research Site

Rozzano, Italy, 20089

Actively Recruiting

34

Research Site

Udine, Italy, 33100

Not Yet Recruiting

35

Research Site

Vicenza, Italy, 36100

Actively Recruiting

36

Research Site

Chūōku, Japan, 104-0045

Actively Recruiting

37

Research Site

Fukuoka, Japan, 812-8582

Actively Recruiting

38

Research Site

Hidaka-shi, Japan, 350-1298

Actively Recruiting

39

Research Site

Kashiwa, Japan, 277-8577

Actively Recruiting

40

Research Site

Kitaadachi-gun, Japan, 362-0806

Actively Recruiting

41

Research Site

Kōtoku, Japan, 135-8550

Not Yet Recruiting

42

Research Site

Nagoya, Japan, 464-8681

Actively Recruiting

43

Research Site

Osaka, Japan, 541-8567

Actively Recruiting

44

Research Site

Osaka, Japan, 558-8558

Withdrawn

45

Research Site

Suita-shi, Japan, 565-0871

Actively Recruiting

46

Research Site

Yokohama, Japan, 241-8515

Actively Recruiting

47

Research Site

Bialystok, Poland, 15-027

Withdrawn

48

Research Site

Warsaw, Poland, 02-034

Withdrawn

49

Research Site

Barcelona, Spain, 08035

Actively Recruiting

50

Research Site

Barcelona, Spain, 08036

Actively Recruiting

51

Research Site

Elche, Spain, 03203

Actively Recruiting

52

Research Site

Madrid, Spain, 28007

Actively Recruiting

53

Research Site

Málaga, Spain, 29010

Actively Recruiting

54

Research Site

Ourense, Spain, 32005

Actively Recruiting

55

Research Site

Oviedo, Spain, 33011

Actively Recruiting

56

Research Site

Santander, Spain, 39008

Actively Recruiting

57

Research Site

Valencia, Spain, 46010

Actively Recruiting

58

Research Site

Kaohsiung City, Taiwan, 80756

Actively Recruiting

59

Research Site

Tainan, Taiwan, 704

Actively Recruiting

60

Research Site

Taipei, Taiwan, 11217

Actively Recruiting

61

Research Site

Taoyuan, Taiwan, 33305

Actively Recruiting

62

Research Site

Adapazarı, Turkey (Türkiye), 54100

Withdrawn

63

Research Site

Erzurum, Turkey (Türkiye), 25240

Withdrawn

64

Research Site

Fatih-Istanbul, Turkey (Türkiye), 34098

Withdrawn

65

Research Site

Istanbul, Turkey (Türkiye), 34722

Withdrawn

66

Research Site

Bristol, United Kingdom, BS2 8ED

Withdrawn

67

Research Site

Dundee, United Kingdom, DD1 9SY

Actively Recruiting

68

Research Site

Headington, United Kingdom, OX3 7LJ

Actively Recruiting

69

Research Site

London, United Kingdom, E1 1BB

Not Yet Recruiting

70

Research Site

Norwich, United Kingdom, NR4 7UY

Actively Recruiting

Loading map...

Research Team

A

AstraZeneca Clinical Study Information Center

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | DecenTrialz